Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma. Issue 8 (1st July 2018)

• Record Type: Journal Article
• Authors: Tsuchiya, Atsunori; Ogawa, Masahiro; Watanabe, Yusuke; Kimura, Naruhiro; Hayashi, Kazunao; Suda, Takeshi; Terai, Shuji
• Is Part Of: Clinical case reports. Volume 6:Issue 8(2018)
• Page Start: 1643
• Page End: 1644
• Publication Date: 2018-07-01
• Subjects: sorafenib -- aortic dissection -- vascular endothelial growth factor pathway inhibitor; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.1674
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: Our case highlights the need for caution during vascular endothelial growth factor pathway inhibitor (VPI) therapy and for the occurrence of aortic dissection. If Stanford classification type A aortic dissection occurs during VPI therapy, surgical intervention should be considered to prevent cardiac tamponade if the patient's clinical condition permits it. Abstract : Our case highlights the need for caution during vascular endothelial growth factor pathway inhibitor (VPI) therapy and for the occurrence of aortic dissection. If Stanford classification type A aortic dissection occurs during VPI therapy, surgical intervention should be considered to prevent cardiac tamponade if the patient's clinical condition permits it.